US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News
This article was originally published in Scrip
This past week in US regulatory, legislative, legal and political news affecting the biopharmaceutical industry included the indictment of a former GlaxoSmithKline PLC senior-level manager, who went from being regarded as one of the world's top protein biochemists to a becoming a thief, scheming with one of her coworkers to steal trade secrets from the London-based drug and vaccine maker; the Senate Health panel chairman's decision to take a step-by-step approach for overhauling the US biomedical enterprise, which ignores several measures, like one focused on antibiotics development, that were included in the House 21st Century Cures Act; and threats by House and Senate lawmakers to bring criminal contempt actions against former Turing Pharmaceuticals Inc. CEO Martin Shkreli if he ignores subpoenas to testify and turn over documents about why his firm hiked up the price of a more than 60-year-old drug; plus other Washington news.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.